ATE142643T1 - Wachstumsinhibierender faktor und für den wachstumsinhibierenden faktor kodierender cdns - Google Patents

Wachstumsinhibierender faktor und für den wachstumsinhibierenden faktor kodierender cdns

Info

Publication number
ATE142643T1
ATE142643T1 AT91401221T AT91401221T ATE142643T1 AT E142643 T1 ATE142643 T1 AT E142643T1 AT 91401221 T AT91401221 T AT 91401221T AT 91401221 T AT91401221 T AT 91401221T AT E142643 T1 ATE142643 T1 AT E142643T1
Authority
AT
Austria
Prior art keywords
growth inhibiting
inhibiting factor
growth
coding
cdns
Prior art date
Application number
AT91401221T
Other languages
English (en)
Inventor
Shoji Tsuji
Tadashi Miyatake
Yoko Uchida
Yasuo Ihara
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2119620A external-priority patent/JP2815461B2/ja
Priority claimed from JP2410164A external-priority patent/JP2904935B2/ja
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE142643T1 publication Critical patent/ATE142643T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT91401221T 1990-05-09 1991-05-07 Wachstumsinhibierender faktor und für den wachstumsinhibierenden faktor kodierender cdns ATE142643T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2119620A JP2815461B2 (ja) 1990-05-09 1990-05-09 神経栄養活性抑性物質
JP2410164A JP2904935B2 (ja) 1990-10-19 1990-12-13 神経栄養活性抑制物質
JP41016590 1990-12-13

Publications (1)

Publication Number Publication Date
ATE142643T1 true ATE142643T1 (de) 1996-09-15

Family

ID=27313865

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91401221T ATE142643T1 (de) 1990-05-09 1991-05-07 Wachstumsinhibierender faktor und für den wachstumsinhibierenden faktor kodierender cdns

Country Status (4)

Country Link
US (1) US5214031A (de)
EP (1) EP0458673B1 (de)
AT (1) ATE142643T1 (de)
DE (1) DE69121964T2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0567645B1 (de) * 1990-12-13 1999-04-14 Takeda Chemical Industries, Ltd. DNA welche für einen Inhibitor der neutropen Aktivität kodiert und seine Verwendung
US5916871A (en) * 1992-04-27 1999-06-29 Kansas State University Research Foundation Inhibitory factor
JPH07508878A (ja) * 1992-04-27 1995-10-05 カンザス ステイト ユニバーシティ リサーチ ファウンデーション 阻害因子
CA2108622A1 (en) * 1992-10-19 1994-04-20 Yoko Uchida Growth inhibitory factor
ES2276393T3 (es) * 1994-04-25 2007-06-16 Genentech, Inc. Cardiotrofina y sus usos.
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US7258983B2 (en) 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor

Also Published As

Publication number Publication date
EP0458673A1 (de) 1991-11-27
EP0458673B1 (de) 1996-09-11
DE69121964D1 (de) 1996-10-17
DE69121964T2 (de) 1997-03-27
US5214031A (en) 1993-05-25

Similar Documents

Publication Publication Date Title
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
FI961438A0 (fi) beta-amyloidiproteiinituotannon estäjiä
RU97105008A (ru) Способ лечения диспластического сколиоза у детей
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
ATE136777T1 (de) Behandlung von schlafstörungen unter verwendung bestimmter antidepressiva, z.b. nefazodon
ATE142643T1 (de) Wachstumsinhibierender faktor und für den wachstumsinhibierenden faktor kodierender cdns
DE69129267D1 (de) Methode zur behandlung intestinaler krankheiten
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE69918145D1 (de) Verwendung von diltiazem zur behandlung von pathologien der netzhaut
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE60228988D1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
GR3017358T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants.
DE69626916D1 (de) Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
ATE189385T1 (de) Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems
ES2017618B3 (es) Procedimiento para producir sustancias que tengan sus germenes matados o que estan debilitadas en su virulencia, asi como el empleo de las mismas
DK120892D0 (da) Treatment and prophylaxis of diseases caused by parasites, fungi or bacteria
GR3032531T3 (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
ATE232098T1 (de) Verwendung von efaroxan zur herstellung eines arzneimittels zur behandlung von huntington krankheit
ITPD910013A1 (it) Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.
Latimer ROOT ZONE CUPRIC HYDROXIDE TREATMENT ENHANCES SUBSEQUENT GROWTH OF TOMATO, BUT NOT PEPPER, TRANSPLANTS
YAN Clinical investigation of double eyelid operation combining with entropion correction
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
ZA921101B (en) Use of tetra: Hydro-thieno-pyrido-indole derivatives for the prepartion of a medicine for the treatment of skin disorders.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties